HUTCHMED: Audit Committee - Terms of Reference
Apr 17 04:37 ET
HUTCHMED: Notification letter to non-registered shareholders and reply form: (1) Annual General Meeting ("AGM"); and (2) Notice of publication of the 2023 Annual Report, Circular, Notice of AGM and Form of Proxy in relation to the AGM and 2023 Sustainabili
Apr 8 04:36 ET
HUTCHMED: Notification letter to registered holders and reply form: (1) Annual General Meeting ("AGM"); and (2) Notice of publication of the 2023 Annual Report, Circular, Notice of AGM and Form of Proxy in relation to the AGM and 2023 Sustainability Report
Apr 8 04:36 ET
HUTCHMED: 2023 Annual Report and Notice of Annual General Meeting
Apr 8 04:35 ET
HUTCHMED: Form of Proxy for Use at the Annual General Meeting
Apr 8 04:34 ET
HUTCHMED: Notice of Annual General Meeting
Apr 8 04:33 ET
HUTCHMED: Notice of Annual General Meeting; Proposals for Re-election of Directors and General Mandates to Issue New Shares and Repurchase Shares
Apr 8 04:33 ET
HUTCHMED: 2023 Sustainability Report
Apr 8 04:31 ET
HUTCHMED: 2023 Annual Report
Apr 8 04:30 ET
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Apr 5 04:33 ET
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended March 31, 2024
Apr 2 04:19 ET
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Apr 2 00:27 ET
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Mar 27 20:00 ET
HUTCHMED: Letters to non-registered shareholders and reply form: New Arrangements on Dissemination of Corporate Communications
Mar 22 05:29 ET
HUTCHMED: Letters to registered shareholders and reply form: New Arrangements on Dissemination of Corporate Communications
Mar 22 05:26 ET
HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Mar 21 20:00 ET
HUTCHMED: Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
Mar 14 05:04 ET
HUTCHMED: Vesting of awards under the Long Term Incentive Plan
Mar 5 03:32 ET
HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended February 29, 2024
Mar 1 03:39 ET
HUTCHMED: Publication of Form 20-F
Feb 28 07:41 ET
No Data
No Data